(The above displayed are just writers’ own opinions and for readers’ reference only. Financial markets are volatile and please be careful of the risks.)NOTICE
Investment involves risk. It is as likely that losses will be incurred rather than profits made as a result of buying and selling investment and financial products. Before investment, you should be aware of all the risks involved and carefully consider your investment objectives, trading experience, and level of risk acceptance. If you have any question, please seek advice from an independent professional advisor.
嚴兆基
恆 指 及 股 票 推 介
2016-05-23
恆 指 及 股 票 推 介
一週回顧
05月16日
05月17日
05月18日
05月19日
05月20日
升 / 跌
星期一
星期二
星期三
星期四
星期五
港股成交金額 (億港元)
564
593
586
555
525
恒生指數
19883
20118
19826
19694
19852
+ 133
國企指數
8312
8425
8301
8243
8303
+ 2
日經平均指數
16466
16652
16644
16646
16736
+ 324
杜瓊斯工業指數
17710
17529
17526
17435
17500
- 35
股份推介: 三生製藥(1530)
建議 : 買入 ($8.00)
止蝕位 : $7.50 目標價:$10.00
理由: 三生製藥現價值博
三生製藥(1530)主要於中國從事生物製藥產品的開發、生產及銷售。集團專注於腫瘤科及腎科兩大治療領域,共銷售11種產品。核心產品包括治療血小板減少症的特比澳及治療貧血症的益比澳。集團2015年純利5.26億元人民幣,按年升80.4%,期內收入16.73億元,按年升47.95%。MSCI公布半年度檢討結果,三生製藥獲納入MSCI中國指數,將於5月31日收市後生效。三生製藥股價近期受壓,提供一個良好介入機會,筆者建議投資者於8元買入,目標價10元,止蝕定於7.5元。
(筆者嚴兆基為證監會持牌人士, 並沒持有上述股份權益)
風險聲明:-
本文提供之內容僅供參考 並不構成要約、招攬或邀請、宣傳、誘使、任何不論種類或形式之申述或立任何交易的任何建議或推薦。若干投資產品並非適合每位投資者, 投資者須因應本身之投資經驗、投資目標、財政資源及其他相關條件, 小心衡量本身是可適合參予有關買賣。投資產品的價格及其收益可升亦可跌, 在若干情況下投資者可能會損失全部資本。
Investment involves risk. It is as likely that losses will be incurred rather than profits made as a result of buying and selling investment and financial products. Before investment, you should be aware of all the risks involved and carefully consider your investment objectives, trading experience, and level of risk acceptance. If you have any question, please seek advice from an independent professional advisor.
© 2015 SUCCESS FINANCE GROUP. All Rights Reserved.